Henry Schein Beats Q2 Estimates, Raises Full-Year Outlook on Strong Dental Sales
HSIC sits 42% above its 52-week low of $61.945.
Summary
Henry Schein reported strong Q2 results with net sales rising 6.7% to $3.5 billion and non-GAAP EPS of $1.27, up from $1.10 a year ago. Internal sales growth accelerated to 4.6%, driven by a 5.9% increase in global dental merchandise sales. The company raised its full-year 2026 guidance, now expecting adjusted EPS of $5.29 to $5.39, up from the prior range of $5.23 to $5.37, and sales growth of 4.5% to 5.5%, up from 3% to 5%. Additionally, Henry Schein now sees 2026 adjusted EBITDA growing mid- to high-single digits, compared to its previous outlook of mid-single-digit growth. The company repurchased $200 million in shares during the quarter, bringing year-to-date buybacks to $325 million under its $850 million program. The results and raised guidance follow a major leadership restructuring and suggest the operational overhaul is yielding margin improvements.
At the time of this announcement, HSIC was trading at $88.07 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $9.9B. The 52-week trading range was $61.95 to $89.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.